Skip to main content
NCBI home page
Annals of Surgery logoLink to Annals of Surgery
. 1991 Mar;213(3):219–221. doi: 10.1097/00000658-199103000-00006

Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10-year follow-up.

J Estape 1, J J Grau 1, F Lcobendas 1, J Curto 1, M Daniels 1, N Viñolas 1, C Pera 1
PMCID: PMC1358330  PMID: 1900148

Abstract

Seventy consecutive patients were entered in a two-arm randomized trial after surgical resection for locally advanced gastric cancer. In the first arm, 37 patients were included as a control group, receiving no further treatment after surgery. In the second arm, 33 patients were treated with adjuvant chemotherapy consisting of mitomycin C (MMC), 20 mg/m2 administered intravenously once every 6 weeks for four consecutive cycles. All patients in both arms were followed in the same way for 5 years. At 5 years 23 of 37 patients in the control arm and 7 of 33 patients in the treatment arm were dead because of relapse. Actuarial survival curve was statistically significant in favor of patients given adjuvant MMC (p less than 0.001). After 10 years follow-up, 31 of 37 patients in the control arm and 16 out of 33 patients in the treatment arm were dead because of relapse, the statistical differences continuing in the actuarial survival curve in favor of treated patients (p less than 0.01). The best advantages of adjuvant treatment were observed in the T3N0M0 stage. The most frequent relapse site was the peritoneal cavity and the relapse pattern shows special decrease in liver metastases in treated patients. Toxicity was acute and mild. No delayed toxicity or second malignancies were observed. These data suggest that adjuvant MMC after resected surgery of gastric cancer is a successful treatment and its effects are still evident after 10 years of follow-up.

Full text

PDF
219

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alcobendas F., Milla A., Estape J., Curto J., Pera C. Mitomycin C as an adjuvant in resected gastric cancer. Ann Surg. 1983 Jul;198(1):13–17. doi: 10.1097/00000658-198307000-00004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Douglass H. O., Jr Gastric cancer: overview of current therapies. Semin Oncol. 1985 Sep;12(3 Suppl 4):57–62. [PubMed] [Google Scholar]
  3. Engstrom P. F., Lavin P. T., Douglass H. O., Jr, Brunner K. W. Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275). Cancer. 1985 May 1;55(9):1868–1873. doi: 10.1002/1097-0142(19850501)55:9<1868::aid-cncr2820550904>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  4. Frei E., 3rd Curative cancer chemotherapy. Cancer Res. 1985 Dec;45(12 Pt 1):6523–6537. [PubMed] [Google Scholar]
  5. Hattori T., Inokuchi K., Taguchi T., Abe O. Postoperative adjuvant chemotherapy for gastric cancer, the second report. Analysis of data on 2873 patients followed for five years. Jpn J Surg. 1986 May;16(3):175–180. doi: 10.1007/BF02471090. [DOI] [PubMed] [Google Scholar]
  6. Higgins G. A., Amadeo J. H., Smith D. E., Humphrey E. W., Keehn R. J. Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology, Group report. Cancer. 1983 Sep 15;52(6):1105–1112. doi: 10.1002/1097-0142(19830915)52:6<1105::aid-cncr2820520629>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  7. Hirono M., Niimoto M., Toge T., Hattori T., Oride M., Nakajima T., Hirata K., Kimura T., Nakazato H., Iwanaga T. A cohort study on second malignancies in gastrectomized patients with gastric cancer. I. Second malignancies other than cancer of the gastric remnant. Jpn J Surg. 1986 Sep;16(5):336–343. doi: 10.1007/BF02470556. [DOI] [PubMed] [Google Scholar]
  8. Hirono M., Niimoto M., Toge T., Hattori T., Oride M., Nakajima T., Hirata K., Kimura T., Nakazato H., Iwanaga T. A cohort study on second malignancies in gastrectomized patients with gastric cancer. II. Second malignancies in the gastric remnant. Jpn J Surg. 1986 Sep;16(5):344–350. doi: 10.1007/BF02470557. [DOI] [PubMed] [Google Scholar]
  9. Ichihashi H., Kondo T., Nakazato H. [Clinical results of a randomized controlled trial on the effect of adjuvant immunochemotherapy using Esquinon and Krestin in patients with curatively resected gastric cancer--7-year survival--Cooperative Study Group for Cancer Immunochemotherapy, Tokai Gastrointestinal Oncology Group]. Gan To Kagaku Ryoho. 1987 Sep;14(9):2758–2766. [PubMed] [Google Scholar]
  10. Inokuchi K. Prolonged survival of gastric cancer patients on a specific adjuvant chemotherapy. Jpn J Surg. 1984 Sep;14(5):351–359. doi: 10.1007/BF02469540. [DOI] [PubMed] [Google Scholar]
  11. Kikuchi K., Kunii Y., Kikuchi S. [The problems of postoperative adjuvant chemotherapy in gastric cancer]. Gan To Kagaku Ryoho. 1987 Apr;14(4):1136–1142. [PubMed] [Google Scholar]
  12. Koyama S., Ozaki A., Iwasaki Y., Sakita T., Osuga T., Watanabe A., Suzuki M., Kawasaki T., Soma T., Tabuchi T. Randomized controlled study of postoperative adjuvant immunochemotherapy with Nocardia rubra cell wall skeleton (N-CWS) and Tegafur for gastric carcinoma. Cancer Immunol Immunother. 1986;22(2):148–154. doi: 10.1007/BF00199130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Peto R., Pike M. C. Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data. Biometrics. 1973 Sep;29(3):579–584. [PubMed] [Google Scholar]
  14. Wilson R. E. Surgical considerations in gastric cancer. Semin Oncol. 1985 Sep;12(3 Suppl 4):63–68. [PubMed] [Google Scholar]
  15. Yoshida K., Ikeuchi H., Kano K., Machida T., Takahashi M., Miura Y., Miura N. Results of surgical treatment of gastric cancer--special reference to pathological findings. Tohoku J Exp Med. 1984 Sep;144(1):57–62. doi: 10.1620/tjem.144.57. [DOI] [PubMed] [Google Scholar]
  16. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3. 1973 Mar;4(2):31–42. [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES